United Therapeutics Corporation
UTHR
Classificação em ações
#999
United Therapeutics Corporation, a biotechnology firm, is dedicated to... United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Preço da ação
$551.89
Valor de mercado
$23.67B
Variação (1 dia)
1.61%
Variação (1 ano)
27.55%
País
US
Negociar United Therapeutics Corporation (UTHR)
Categoria
Healthcare
Rácio P/E de United Therapeutics Corporation (UTHR)
Rácio P/E em October 2026 TTM: 17.86
De acordo com os últimos relatórios financeiros e o preço das ações da United Therapeutics Corporation, o rácio P/E atual (TTM) é 17.86. No final de 2023, a empresa tinha um P/E de 10.45.
Histórico do rácio P/E da United Therapeutics Corporation de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 17.86 | 33.91% |
| 2024 | 13.34 | 27.71% |
| 2023 | 10.45 | -39.94% |
| 2022 | 17.40 | -14.68% |
| 2021 | 20.39 | 56.46% |
| 2020 | 13.03 | -135.30% |
| 2019 | -36.92 | -559.18% |
| 2018 | 8.04 | -48.39% |
| 2017 | 15.58 | 76.97% |
| 2016 | 8.80 | -20.38% |
| 2015 | 11.06 | -39.73% |
| 2014 | 18.34 | -43.45% |
| 2013 | 32.44 | 254.89% |
| 2012 | 9.14 | -26.27% |
| 2011 | 12.40 | -63.01% |
| 2010 | 33.51 | -76.77% |
| 2009 | 144.23 | -530.83% |
| 2008 | -33.48 | -132.08% |
| 2007 | 104.36 | 517.01% |
| 2006 | 16.91 | -30.30% |
| 2005 | 24.27 | -61.78% |
| 2004 | 63.49 | -230.50% |
| 2003 | -48.65 | 233.78% |
| 2002 | -14.58 | 157.39% |
| 2001 | -5.66 | 50.91% |
| 2000 | -3.75 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 28.78 | 61.12% |
US
|
|
| -28.36 | -258.75% |
US
|
|
| -24.57 | -237.52% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 69.78% |
NL
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.